Skip to main content

GLP-1 RAs Reduce Risk for Clinically Important Kidney, CVD Outcomes

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 6, 2024.

via HealthDay

FRIDAY, Dec. 6, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes, according to research published online Nov. 25 in The Lancet Diabetes & Endocrinology.

Sunil V. Badve, Ph.D., from the University of New South Wales in Sydney, and colleagues conducted a meta-analysis of randomized controlled trials that compared a GLP-1 RA to placebo among participants with type 2 diabetes. Post hoc, the SELECT trial, which enrolled participants with cardiovascular disease and a body mass index of 27 kg/m2 or greater without diabetes, was included. The meta-analysis included 11 trials with 85,373 participants (67,769 with type 2 diabetes).

The researchers found that GLP-1 RAs reduced the composite kidney outcome, kidney failure, major adverse cardiovascular events (MACE), and all-cause death compared with placebo (hazard ratios, 0.82, 0.84, 0.87, and 0.88, respectively) in participants with type 2 diabetes. On inclusion of the SELECT trial, the effect on the composite kidney outcome, kidney failure, MACE, and all-cause death was similar (hazard ratios, 0.81, 0.84, 0.86, and 0.87, respectively), with no evidence of heterogeneity between the trials. The GLP-1 RA and placebo groups had no differences in the risk for serious adverse events, including acute pancreatitis and severe hypoglycemia.

"Taken together, these results and the breadth of the benefits observed support an important role for GLP-1 receptor agonists as kidney-protective and heart-protective medications that could play an important role in addressing the global burden of noncommunicable diseases," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Novel Biomarker Risk Prediction Models Examined in Chronic Kidney Disease

FRIDAY, Aug. 22, 2025 -- For adults with nondialysis chronic kidney disease (CKD), risk prediction models incorporating novel biomarkers show comparable discrimination to...

Seniors With Certain Cardiovascular Diseases Saw Life's Essential 8 Scores Decline 2013 to 2018

WEDNESDAY, Aug. 20, 2025 -- From 2013 to 2018, older adults with heart failure, stroke, and hypertension experienced significant declines in Life's Essential 8 (LE8) scores...

High Metabolic Syndrome Severity Linked to Development of CKD

FRIDAY, Aug. 15, 2025 -- High metabolic syndrome (MetS) severity, expressed by the continuous metabolic syndrome severity score (cMetS-S), is associated with development of...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.